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Type 2 diabetes mellitusAbstract Background: Rheumatoid arthritis (RA) patients are at an increased risk of developing
type-2 diabetes mellitus (T2DM) compared to the general population. Interferon-c (IFN-c) was
found to have a role in both RA and T2DM.
Aim of the work: To investigate the role of IFN-c and its +874T/A gene polymorphism in the
development of T2DM in RA patients.
Patients and methods: IFN-c level and its +874T/A gene polymorphism were investigated in 70
RA patients with T2DM and in 80 without, in addition to 150 healthy controls.
Results: The level of IFN-c was significantly higher in RA patients with (465 ± 64.4 pg/ml) and
without (219 ± 50.3 pg/ml) T2DM compared to controls (110 ± 18 pg/ml) (p< 0.0001). IFN-c
+874T/A genotyping showed a significant increase in the frequency of AA genotype (42.9%)
and a significant decrease in TT genotype (14.2%) in RA patients with T2DM compared to those
without; similarly, the frequency of the T-allele was significantly lower (p< 0.05) and the A-allele
increased (p< 0.05); however no significant differences in the genotypes distribution were found
between non-diabetic RA patients and healthy controls. The TT-genotyped RA patients with
(539.6 ± 4 pg/ml) and without (260 ± 59.6 pg/ml) diabetes had higher serum IFN-c levels com-
pared to other genotypes (p< 0.001), while in controls, no significant difference in IFN-c levels
according to genotype was observed.
278 A.A. Mahmoud et al.Conclusions: Serum IFN-c and its gene polymorphism may play a role in the susceptibility of
RA patients to T2DM. The homozygous genotypes AA and TT seem to be more commonly asso-
ciated with diabetes in RA patients with special contribution of the A-allele.
 2015 The Authors. Publishing services provided by Elsevier B.V. on behalf of Egyptian Society of
Rheumatic Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease charac-
terized by progressive inflammation and involvement of
T-cells, B-cells and pro-inflammatory cytokines [1].
Many cytokines are key players in the pathogenesis of RA
including tumor necrosis-a [2] and interleukin-6 (IL-6) [3] with
involvement of their gene polymorphisms.
Patients with RA are at an increased risk of insulin resis-
tance and type 2 diabetes mellitus (T2DM) due to the raised
levels of systemic inflammation [4] and metabolic syndrome
has been frequently reported in Egyptian RA patients [5].
Interferon-c (IFN-c), a T-helper 1 (Th1) cytokine has an
important role in the pathogenesis of RA as it serves as a mar-
ker of activation of Th1 cells which promote and amplify
autoimmune diseases, furthermore, it is involved in the patho-
genesis of T2DM [3,4]. This cytokine has the potential to direct
the inflammatory response by upregulating a variety of pro-
inflammatory mediators including TNF-a and IL-6. More-
over, data suggest that IFN-c may also be able to directly
enhance activation of the pro-inflammatory nuclear transcrip-
tion factor-jB (NF-jB) under certain conditions [6]. A cyto-
sine–adenine (CA) repeat polymorphism was reported in the
first intron of the IFN-c gene and found to affect transcription.
In addition, an adenine (7) to thymine (T) transition at posi-
tion +874 (rs2430561) has been associated with increased
IFN-c expression [8]. Association of a polymorphic
microsatellite located in the first intron of the IFN-c gene,
which is in complete linkage disequilibrium with the
rs2430561 functional variant; with susceptibility to RA was
reported [9]. Also, the association between IFN-c gene +874
(A/T) polymorphisms and T2DM was reported [7]. However,
other studies failed to confirm the presence of association
between that gene polymorphism and RA [10,11].
The aim of the present study was to assess the serum IFN-c
levels and IFN-c gene +874 (A/T) polymorphism in RA
patients with and without T2DM in comparison to the level
in control subjects.
2. Patients and method
2.1. Study groups
The study included 150 RA patients, recruited from the
Rheumatology Department, Sohag University Hospital, who
satisfied the criteria of the American College of Rheumatol-
ogy/European League Against Rheumatism Collaborative ini-
tiative for the classification of rheumatoid arthritis [12].
Seventy of these RA patients developed T2DM during the
course of disease. The diagnosis of T2DM was considered
according to the American Diabetes Association Criteria
[13]. 150 healthy subjects, their age and sex were matched tothe patients served as controls. Written informed consents
were obtained from all enrollees and the study was carried
out in accordance with the guidelines of the ethics committee
of Faculty of Medicine, Sohag University and to the tenets
of Helsinki declaration.
For all participants the following tests were done;
C-reactive protein (CRP), fasting blood glucose (FBG), lipid
profile parameters: total cholesterol (TC), high density lipopro-
tein (HDL-C), triglyceride and low density lipoprotein (LDL-C).
2.2. Assessment of serum IFN-c and IFN-c +874 T/A
Approximately 5 ml venous blood samples were collected from
the participants after an overnight fasting and divided into two
parts; one part (2 ml) was taken in EDTA tubes for DNA
extraction and the other part (3 ml) was taken in plain tubes
and the serum was separated after centrifuged at 3000 rpm
for 15 min and used for routine laboratory tests and for the
estimation of IFN-c protein levels using ELIZA test kit sup-
plied by R&D system. The puffy coats of EDTA samples were
obtained after centrifugation at 3000 rpm for 15 min and used
for DNA extraction using QIAamp kit supplied by Qiagen
(USA).
2.3. Genotyping
Genotyping for the polymorphism of IFN-c +874 T/A was
carried out by the amplification refractory mutation system-
polymerase chain reaction (ARMS-PCR) assay in two separate
PCR reaction mixtures according to Sen et al. with modifica-
tions [14]. Two forward primes (one for A-allele; and the other
for T-allele) and a common reverse primer were used for IFN-
c +874 T/A genotyping as following: forward A; 5-TTCTTA
CAACACAAAATCAAATCA-3, forward T; 5-TCAACAAA
GCTGATACTCCA-3; and common reverse primer; 5-
TTCTTACAACACAAAATCAAATCT-3, in addition, an
internal control primer pair to amplify human growth hor-
mone (HGH) sequence to check for successful PCR amplifica-
tion as following; forward; 5-CCTTC CAACCATTCCCTTA-
3 and reverse; 5-TCACGGATTTCTGTTGTGTTTC-3.
Amplification was carried out in a thermocycler (Biometra,
Germany), using 25 ll reaction volume containing the follow-
ing; 2.5 ll, 10 PCR buffer (500 KCl, 100 Mm Tris–HCl,
1.0% Triton X-100), 0.75 ll 50 mM MgCl2, 0.5 ll 10 mM
dNTPs, 1.0 ll, of each primer (10 pmol/ml), 1.0 ll of template
DNA and 0.125 ll Taq polymerase (5 U/ll). The PCRs were
performed in the following conditions: 95 C for 4 min, fol-
lowed by 10 cycles of 95 C for 15 s, 62 for 50 s and 72 C
for 40 s, and then 25 cycles of 95 C for 20 s, 49 C for 50 s
and 72 C for 50 s, and 72 C for 10 min for the final extension.
The amplified products were separated by electrophoresis on
2% agarose gel stained with 0.5 lg/ml ethidium bromide and
Table 1 Demographic and laboratory data of the rheumatoid arthritis patients with and without type-2 diabetes mellitus and the
control.
Parameter RA patients (n= 150) Control (n= 150) p
With T2DM Without T2DM
Female:male 50/20 (2.5:1) 50/30 (1.7:1) 105/45 (2.3:1) >0.05
Age (years) 57.8 ± 4.6 57.4 ± 4.3 56 ± 5.2 >0.05
Dis. duration (years) 6.4 ± 2 7 ± 2.4 – >0.05
Body mass index 26.2 ± 3.2 24.8 ± 2.5 25.6 ± 3 >0.05
FBG (mg/dl) 153.4 ± 16.7 95 ± 11.5 94 ± 10.5 <0.0001
TC (mg/dl) 260.9 ± 65.2 194 ± 30 186.9 ± 12.4 <0.0001
TG (mg/dl) 208.6 ± 60.8 136.6 ± 31 109 ± 29.4 <0.0001
HDL-C (mg/dl) 30 ± 7 33 ± 8 37.5 ± 4.5 <0.05
LDL-C (mg/dl) 168.4 ± 63.2 133 ± 18 101.8 ± 14.9 <0.001
CRP (mg/dl) 19.4 ± 3.3 9.5 ± 2.2 1.9 ± 0.1 <0.0001
INF-c (pg/ml) 465 ± 64.4 219 ± 50.3 110 ± 18 <0.0001
RA: rheumatoid arthritis, T2DM: type-2 diabetes mellitus, FBG: fasting blood glucose, TC: total cholesterol, TG: triglycerides, HDL-C: high
density lipoprotein-cholesterol, LDL-C; low density lipoprotein-cholesterol, CRP:C-reactive protein, INF-c: interferon-gamma.
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obtained; 261-bp for IFN-c and 426-bp for HGH.
2.4. Statistical analysis
Data were expressed as mean ± SD or number and percent.
Genotype distribution was tested for deviation from HWE
(Hardy–Weinberg equilibrium) by x2 analysis. Fisher Exact
test was used to compare the genotypes frequencies in the
patients and the controls. Continuous data were compared
using Mann–Whitney and ANOVA tests. A two-tailed value
of p< 0.05 was considered statistically significant. All statisti-
cal calculations were performed using the computer program
SPSS (Statistical Package for the Social Science; SPSS, Chi-
cago, IL, version 16 for Microsoft Windows, USA).3. Results
The clinical and laboratory data of the participants are repre-
sented in Table 1. There were no significant differencesFigure 1 Correlation between the interferon-c serum level and the
mellitus (T2DM) (left) and those without T-2DM (right).between the participants regarding age, sex or disease duration
(p> 0.05). Diabetic RA patients had significantly higher
FBG, TC, LDL-C and lower HDL-C compared to non-
diabetic RA and healthy controls (p< 0.05).
The IFN-c serum levels were significantly higher in RA
patients (diabetic or non-diabetic) compared to controls
(p< 0.0001). Also there was a significant correlation between
IFN-c level and CRP level in both groups of RA patients
(Fig. 1). In addition a significant correlation was found
between FBG and IFN-c levels in diabetic RA patients
(r= 0.36, p= 0.002).
The IFN-c +874 T/A gene polymorphism genotyping
showed that there was no deviation from HWE for both the
patients and the controls. Fig. 2 shows agarose gel elec-
trophoresis of interferon-c +874 T/A gene polymorphism.
AA genotype showed a significant increase, TT genotype
exhibited a significant decrease in diabetic RA patients com-
pared to non-diabetic RA patients (p< 0.05). The frequency
of the T-allele was significantly decreased (p< 0.05) and the
A-allele significantly increased (p< 0.05) in diabetic RA
patients compared to non-diabetic RA patients. No significantCRP level in rheumatoid arthritis patients with type-2 diabetes
Figure 2 Agarose gel electrophoresis showing interferon-c+874 T/A gene polymorphism. Each genotype is represented by 2 lanes; lanes
1 and 22 represent 100 bp ladder, lanes 2 and 3, 10 and 11, 18 and 19, 20 and 21 represent TT genotypes; Lanes 4 and 5, 12 and 13, 14 and
15, 16 and 17 represent AT genotype; lanes 6 and 7, 8 and 9 represent AA genotype.
Table 2 IFN-c +874T/A genotypes of the rheumatoid arthritis patients with and without type-2 diabetes mellitus and the control.
INF-c +874T/A genotype n (%) RA patients (n= 150) p Controls (n= 150) p
With T2DM (n= 70) Without (n= 80)
TT 10 (14.2) 25 (31.25) <0.05 40 (26.7) >0.05
TA 30 (42.9) 42 (52.5) >0.05 80 (53.3) >0.05
AA 30 (42.9) 13 (16.25) <0.05 30 (20) >0.05
T-allele 50 (35.7) 92 (57.5) <0.05 160 (53.3) >0.05
A-allele 90 (64.3) 68 (42.5) <0.05 140 (46.7) >0.05
INF-c: interferon-gamma, RA: rheumatoid arthritis, T2DM: type-2 diabetes mellitus.
N.B: the number of alleles equals double the number of the participants.
Table 3 Serum INF-c levels according to genotype in
rheumatoid arthritis patients with and without type-2 diabetes
mellitus and the control.
INF-c (pg/ml) Genotype p
TT TA AA
RA patients
With T2DM 539.6 ± 4 504.8 ± 34.7 400.4 ± 38.6 <0.001
Without 260 ± 59.6 212 ± 28.6 176 ± 21.8 <0.001
Controls 113.8 ± 19.2 109.4 ± 18 106.9 ± 16.4 >0.05
INF-c: interferon-gamma, RA: rheumatoid arthritis, T2DM: type-
2 diabetes mellitus.
280 A.A. Mahmoud et al.differences in the genotypes distribution were found between
non-diabetic RA patients and the controls (Table 2). RA
patients (diabetic or non-diabetic) with TT-genotype had high-
est IFN-c levels and those with AA-genotype had the lowest
and patients with TA-genotype had intermediate levels. How-
ever, IFN-c levels didn’t differ according to the genotype in the
controls (Table 3).4. Discussion
In the present study, IFN-c serum levels were found elevated
in RA patients either diabetic or non-diabetic, and significantly
correlated to CRP levels. The elevated levels of pro-
inflammatory cytokines, including IFN-c in RA and their cor-
relation to disease activity have been reported in previous stud-
ies [15–19]. Interferon-c has also been implicated as a
biomarker for radiographic damage [20] and anemia [21] in
RA patients. Diabetic RA patients had significantly elevated
CRP and IFN-c levels compared to non-diabetic RA patients,
indicating more disease activation and immune stimulation in
those patients. RA patients are at an increased risk of insulin
resistance and T2DM due to the associated systemic inflamma-
tion [22].
The findings of IFN-c+874 T/A gene polymorphism geno-
typing were similar to those previously reported [7,10,11], how-
ever this is the first study to investigate the role of IFN-c+874
T/A gene polymorphism in the association of RA patients to
T2DM. IFN-c was found to be involved in the pathogenesis
of diabetes mellitus and the frequency of the low IFN-c pro-
duction allele (A-allele) was found significantly higher in
type-2 diabetics compared to controls [7]. IFN-c +874 T/A
gene polymorphism has been reported to affect its gene expres-
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compared with the TT genotype, while the heterozygous (TA)
genotype has been characterized by intermediate levels [8].
IFN-c +874 T/A gene polymorphism overlap with the middle
of an assumed NF-jB binding site that may be of functional
concerns for the transcription of IFN-c gene [23]. On the other
hand, in a cohort of Brazilian RA patients there was no signif-
icant difference between the patients and controls regarding
the IFN-c +874 T/A polymorphism [24].
Rheumatoid arthritis is characterized by immune dysfunc-
tions with predominance of the pro-inflammatory responses
exhibited by Th1 and Th17. Recent data suggested that
IFN-c had a protective function in RA and involved in the
down-regulation of disease-related chronic inflammation [25].
IFN-c has been suggested to have a key role in the regulation
of visceral adipose tissue inflammatory response and endothe-
lial dysfunction in type 2 diabetes [25]. IFN-c +874 T/A gene
polymorphism was found associated with many diseases,
including infectious diseases as hepatitis B, Helicobacter pylori
gastritis and tuberculosis [26–28] and autoimmune diseases like
SLE and scleroderma [29,30].
A longitudinal study taking into consideration the effect of
medications received, disease activity, radiographic severity
and other components of the metabolic syndrome is recom-
mended to further demonstrate the important role of INF-c
and its gene polymorphism in rheumatoid arthritis and its
associated comorbidities.
In conclusion, IFN-c and its gene polymorphism may play a
role in the susceptibility of RA patients to T2DM. The
homozygous genotypes AA and TT seem to be more com-
monly associated with diabetes in RA patients with special
contribution of the A-allele.
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